Present in 20 different countries, we are one of the Brazilian pharmaceutical companies that most heavily invests in innovation. We offer products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments.
Eurofarma is a fully Brazilian owned multinational pharmaceutical company, recognized since 1972 by the medical community and society at large for promoting access to health and quality of life with affordable, quality and innovative treatments.
With operations in more than 20 countries in South and Central America, Africa and the Caribbean, and 10 strategically distributed manufacturing plants in Latin America, Eurofarma is a front runner in major pharmaceutical segments including Prescription Drugs, Nonprescription Drugs, Generic Drugs, Hospital, Bidding, Oncology, Outsourcing Services and Veterinary Medicine. The company’s broad portfolio encompasses all medical specialties and is a benchmark for central nervous system, anti-infective and hormonal drugs.
Acknowledged for its pioneering spirit and entrepreneurial savviness since its very beginning, Eurofarma has forged national and international partnerships in different cooperation models including licenses, distribution agreements, provision of services in the production sector, joint ventures and co-development, among others. Its innovation-centered pipeline comprises over 200 projects and expansion plans for key global markets.
Its commitment to innovation led to the creation of the Eurofarma Synapsis project in 2017, a partnership and incentive model for startups focused on the development of disruptive healthcare technology. The corporate venture initiative held in partnership with Endeavor concentrates on fostering entrepreneurship. In 2019, the company created the 1st EmergeLabs Eurofarma, a program bringing entrepreneurial scientists and the market together to reinforce its commitment to developing the national health and innovation ecosystem.
|Eurofarma recognizes human capital as its most important asset. The Group employs approximately 7,000 people, more than 5,500 of which are allocated in Brazil. It also has one of the largest medical sales and marketing workforces in the industry, with over 3,000 employees covering approximately 530,000 medical contacts per month.||A company based on solid values that’s growing in a sustainable manner, striving for excellence and feeding on current challenges by taking new steps as if they were the first.|
Known for having one of the best work environments since the early 2000s, Eurofarma ranked among the “Best Companies to Work For” by Exame Você S/A magazine for 10 years and made the “Época GPTW (Great Place to Work)” ranking in 2014. In 2019, the company was named best pharmaceutical company to work for and ranked 13th on the Great Place to Work (GPTW) list. Internationally, the company was recognized for the very first time as the best pharmaceutical company to work for in Central America in the 2020 GPTW ranking for Central America and the Caribbean.
As the only pharmaceutical company to be recognized by the Guia Exame de Sustentabilidade (Exame Sustainability Guide) on four different occasions, Eurofarma strengthened its commitment to the UN Global Compact in 2015 by pledging to support its ten principles. The initiative determines the adoption of business practices based on ethical and responsible values in the areas of environment, human rights, labor relations and anti-corruption. Through a partnership forged with the Ethos Institute in 2017, the company implemented the Sustainability in the Value Chain program with the aim of evaluating and monitoring best practices of its direct suppliers of feedstock.
The company makes social investments via the Eurofarma Institute, founded in 2006. Its social projects have served more than 94,000 people directly, primarily through complementary education, environmental education and training for youth, adults and the elderly.